Urinary abnormality in mixed connective tissue disease predicts development of other connective tissue diseases and decrease in renal function.


Journal

Modern rheumatology
ISSN: 1439-7609
Titre abrégé: Mod Rheumatol
Pays: England
ID NLM: 100959226

Informations de publication

Date de publication:
05 Jan 2022
Historique:
received: 05 10 2020
accepted: 01 03 2021
pubmed: 13 3 2021
medline: 3 6 2022
entrez: 12 3 2021
Statut: ppublish

Résumé

To clarify the clinical significance of development of urinary abnormality in mixed connective tissue disease (MCTD). Forty-one patients with an initial diagnosis of MCTD, followed at five hospitals between April 1, 2000 and December 31, 2013, were included. The relationship between urinary abnormality and various clinical parameters were retrospectively analyzed. Urinary abnormality was defined as proteinuria and/or hematuria detected by urinalysis. Development of other connective tissue diseases (CTDs) was defined as satisfaction of the criteria of each respective disease. Of 41 patients (34 females, 7 males, mean age at diagnosis 42.2 ± 15.2 years), 16 developed urinary abnormality (UrA(+) patients). The total incidences of development of other CTDs were higher in the UrA(+) patients than UrA(-) (62.5% versus 16.0%, p = .01). In the comparison between UrA(+) and UrA(-) patients, there were no significant differences in follow-up duration or last determined estimated glomerular filtration rate (eGFR), although eGFR decreased more significantly in the UrA(+) patients than UrA(-). (-20.2 ± 17.2 vs -6.1 ± 13.8 ml/min/1.73m2, p = .01; -21.0 ± 18.9 vs -6.7 ± 14.1%, p = .03). Urinary abnormality during the clinical course in MCTD is predictive of a higher incidence of developing other CTDs. Furthermore, it might also predict long-term renal prognosis in patients with an initial diagnosis of MCTD.

Identifiants

pubmed: 33706652
doi: 10.1080/14397595.2021.1899602
pii: 6469675
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

155-162

Informations de copyright

© 2021 Japan College of Rheumatology.

Auteurs

Ryo Nishioka (R)

Department of Rheumatology, Kanazawa University Hospital, Kanazawa, Japan.

Takeshi Zoshima (T)

Department of Rheumatology, Kanazawa University Hospital, Kanazawa, Japan.

Satoshi Hara (S)

Department of Rheumatology, Kanazawa University Hospital, Kanazawa, Japan.

Yasunori Suzuki (Y)

Department of Rheumatology, Kanazawa University Hospital, Kanazawa, Japan.

Kiyoaki Ito (K)

Department of Rheumatology, Kanazawa University Hospital, Kanazawa, Japan.

Kazunori Yamada (K)

Department of Hematology and Immunology, Medicine, Kanazawa Medical University Hospital, Ishikawa, Japan.

Akikatsu Nakashima (A)

Department of Rheumatology and Nephrology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.

Yukiko Tani (Y)

Department of Nephrology, Komatsu Municipal HospitalKomatsu, Japan.

Takashi Kawane (T)

Department of Nephrology, Rheumatology, Infectious Disease Medicine, Toyama Red Cross Hospital, Toyama, Japan.

Masayoshi Hirata (M)

Department of Nephrology, Takaoka City Hospital, Takaokarr, Japan.

Ichiro Mizushima (I)

Department of Rheumatology, Kanazawa University Hospital, Kanazawa, Japan.

Mitsuhiro Kawano (M)

Department of Rheumatology, Kanazawa University Hospital, Kanazawa, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH